Barrett’s oesophagus – European Clinical Trials Information Network

Study on Budesonide Tablets for Preventing Esophageal Narrowing in Adults After Cancer Tissue Removal

Wed, 29 Apr 2026 14:26:02 +0000

This clinical trial is focused on preventing a condition called esophageal strictures, which are narrowings in the esophagus that can occur after a procedure known as endoscopic submucosal dissection. This procedure is often used to remove cancerous or pre-cancerous tissue from the esophagus. The study is testing the effectiveness and safety of a medication called budesonide, which is taken as an effervescent tablet that dissolves in the mouth. Budesonide is being compared to a placebo, which is a tablet that looks like the medication but does not contain any active ingredients.

The purpose of the study is to see if taking budesonide for eight weeks can help prevent the formation of esophageal strictures in adults who have undergone the endoscopic procedure. Participants in the study will be randomly assigned to receive either a low dose or a high dose of budesonide, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment.

Throughout the study, participants will take the medication or placebo for a total of eight weeks. The main goal is to determine how many participants remain free of esophageal strictures by the end of the study period. Additionally, the study will track the number of times participants need a procedure called endoscopic dilation, which is used to widen the esophagus if strictures do occur. The results will help determine if budesonide is an effective treatment for preventing esophageal strictures after endoscopic submucosal dissection.

Study on the Safety and Feasibility of Bevacizumab-800CW Imaging for Patients with Barrett’s Esophagus, Colon Cancer, or Gastrointestinal Dysplasia

Wed, 29 Apr 2026 14:25:19 +0000

This clinical trial is focused on studying the safety and practicality of a new imaging technique called immuno-OCT for certain conditions affecting the digestive system. The diseases being studied include Barrett’s esophagus, colon cancer, and gastrointestinal dysplasia. The treatment involves using a special tracer called Bevacizumab-800CW, which is a modified form of the medication Avastin. This tracer is used in combination with a capsule-based imaging device that patients swallow, allowing doctors to capture detailed images of the gastrointestinal tract.

The purpose of the study is to determine if this new imaging method is safe and can be effectively used in patients. During the study, participants will undergo a procedure where the capsule is swallowed and then manually retrieved, capturing high-resolution images of the digestive tract. This imaging technique combines structural imaging with a special type of imaging called near-infrared fluorescence, which helps visualize specific areas of interest, such as potential tumor sites or areas of inflammation.

The study will monitor the safety of the immuno-OCT imaging by tracking any device-related side effects. It will also assess how well the imaging method works in practice. The results from this imaging will be compared to other imaging techniques and tissue analysis to validate its effectiveness. The study is expected to continue until early 2025, with recruitment starting in December 2023.

Study on Detecting Early Barrett’s Esophagus Using Bevacizumab-800CW and Cetuximab-800CW for Patients with Barrett’s Esophagus

Wed, 29 Apr 2026 14:24:17 +0000

This clinical trial is focused on studying a condition known as Barrett’s esophagus, which can sometimes lead to a type of cancer in the esophagus. The study is testing two treatments, bevacizumab and cetuximab, which are given in a special form that allows them to be seen using a technique called fluorescence molecular endoscopy. This technique helps doctors see early changes in the esophagus that might not be visible with regular methods.

The purpose of the study is to see if using these treatments can help detect early signs of cancer in patients with Barrett’s esophagus more effectively than the usual method, which is called high-definition white-light endoscopy. The study will involve giving the treatments by mouth and then using the special endoscopy to look for changes in the esophagus. The researchers want to find out if this method can make it easier and quicker to spot any early signs of cancer.

Participants in the study will receive either the treatments or a placebo, and the researchers will compare the results to see if the new method is better at finding early signs of cancer. The study will also look at the safety of using these treatments in this way. The goal is to improve how early esophageal cancer is detected, which could lead to better outcomes for patients with Barrett’s esophagus.